Newron Pharmaceuticals S.p.A.
NP5
Kedudukan dalam Saham
#17791
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Harga Saham
$10.46
Modal Pasaran
$213.92M
Perubahan (1 hari)
-0.90%
Perubahan (1 tahun)
-39.31%
Negara
IT
Perdagangan Newron Pharmaceuticals S.p.A. (NP5)
Kategori
Healthcare
Modal pasaran bagi Newron Pharmaceuticals S.p.A.(NP5)
Modal Pasaran: $213.92M
Sehingga October 2026, Newron Pharmaceuticals S.p.A. mempunyai modal pasaran sebanyak $213.92M. Ini menjadikan Newron Pharmaceuticals S.p.A. syarikat ke-17791st paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Newron Pharmaceuticals S.p.A. dari 2015 hingga 2026
NP5 berbanding dengan 5 teratas yang paling popular stocks
